Ipramol Steri-Neb (Ipratropium Bromide, Salbutamol)

Ipratropium bromide is an anticholinergic agent that blocks muscarinic receptors on airway smooth muscle. By preventing acetylcholine‑mediated contraction, it reduces bronchoconstriction, allowing the airways to remain open and facilitating easier breathing.

The dosage of Ipramol Steri-Neb is determined by the prescribing clinician based on the patient’s condition, age, and response to therapy. The prescriber will specify the volume of nebulizer solution and frequency of administration appropriate for each individual case.

Safety data for Ipramol Steri-Neb in pregnancy and lactation are limited. Healthcare providers should weigh the potential benefits against any possible risks and discuss these considerations with the patient before initiating therapy.

To order Ipramol Steri-Neb, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Ipramol Steri-Neb combines an anticholinergic (ipratropium) with a short‑acting β2‑agonist (salbutamol), offering additive bronchodilation. Compared with single‑agent bronchodilators, this combination can achieve faster and more pronounced airway opening, especially in patients who have an incomplete response to either component alone.

Store Ipramol Steri-Neb at ambient temperature, preferably below 25 °C. Keep the container tightly sealed, protect it from direct sunlight, moisture, and extreme temperatures, and retain it in its original packaging until use.

Ipramol Steri-Neb is administered via a nebulizer. The prescribed volume of the solution is placed in the nebulizer cup, connected to a compressor, and inhaled through a mouthpiece or mask until the medication is fully aerosolized, typically taking several minutes per session.

Serious risks include paradoxical bronchospasm, severe tachyarrhythmias, hypotension, and allergic reactions such as anaphylaxis. Patients should be monitored for these events, especially during initial dosing or when used in individuals with underlying cardiac conditions.

Ipramol Steri-Neb is contraindicated in patients with known hypersensitivity to ipratropium bromide, salbutamol, or any component of the formulation. It should also be avoided in individuals with severe narrow‑angle glaucoma or urinary retention without medical supervision.